Treatment of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), or Sjögren's syndrome (SS) patients with rituximab, a CD20 antibody that depletes B cells, also decreased the number of circulating Th17 cells and serum IL-17A levels [8], [9]. This evidence concerns the gene IL17A and systemic lupus erythematosus.